Rapport Therapeutics
RAPP
124 hedge funds and large institutions have $1.46B invested in Rapport Therapeutics in 2025 Q3 according to their latest regulatory filings, with 51 funds opening new positions, 37 increasing their positions, 20 reducing their positions, and 9 closing their positions.
467% more first-time investments, than exits
New positions opened: 51 | Existing positions closed: 9
234% more capital invested
Capital invested by funds: $438M → $1.46B (+$1.03B)
85% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 20
51% more funds holding
Funds holding: 82 → 124 (+42)
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
29.54% more ownership
Funds ownership: 105.47% → 135.01% (+30%)
17% more call options, than puts
Call options by funds: $7.6M | Put options by funds: $6.49M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$25.7M |
| 2 |
Goldman Sachs
New York
|
+$21.2M |
| 3 |
BBA
Baker Bros. Advisors
New York
|
+$17.8M |
| 4 |
VPC
Vestal Point Capital
New York
|
+$16.9M |
| 5 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$16.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JJ
Johnson & Johnson
New Brunswick,
New Jersey
|
-$12.7M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$7.55M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$5.33M |
| 4 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$2.43M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$2.38M |
RAPP Hedge Fund Activity: Q3 2025 in Review
124 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Rapport Therapeutics (RAPP) for Q3 2025, worth a combined $1.46B — up 234% from $438M a quarter earlier.
Buyers outnumbered sellers: 51 funds opened new RAPP positions and 9 closed out — a net gain of 42 holders — while 37 added to existing stakes and 20 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $25.7M. The largest seller was Johnson & Johnson, cutting an estimated $12.7M.
- 124 institutional investors held Rapport Therapeutics (RAPP) as of Q3 2025, up from 82 in Q2 2025.
- Funds reported $1.46B of Rapport Therapeutics stock for Q3 2025, up 234% quarter-over-quarter.
- 51 funds opened new Rapport Therapeutics positions in Q3 2025 and 9 closed out, a net change of +42 holders.
- The largest Rapport Therapeutics buyer in Q3 2025 was Fidelity Investments, an estimated $25.7M added.
- The largest Rapport Therapeutics seller in Q3 2025 was Johnson & Johnson, an estimated $12.7M sold.
Based on aggregated 13F filings for Q3 2025.